BRPI0712073A2 - cÉlulas produtoras de polipeptÍdio - Google Patents

cÉlulas produtoras de polipeptÍdio Download PDF

Info

Publication number
BRPI0712073A2
BRPI0712073A2 BRPI0712073-7A BRPI0712073A BRPI0712073A2 BR PI0712073 A2 BRPI0712073 A2 BR PI0712073A2 BR PI0712073 A BRPI0712073 A BR PI0712073A BR PI0712073 A2 BRPI0712073 A2 BR PI0712073A2
Authority
BR
Brazil
Prior art keywords
nucleic acid
producing cells
polypeptide
stop codon
splice
Prior art date
Application number
BRPI0712073-7A
Other languages
English (en)
Inventor
Endl Josef
Kopetzki Erhard
Ploettner Olivier
Schwarz Ursula
Tiefenthaler Georg
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of BRPI0712073A2 publication Critical patent/BRPI0712073A2/pt
Publication of BRPI0712073B1 publication Critical patent/BRPI0712073B1/pt
Publication of BRPI0712073B8 publication Critical patent/BRPI0712073B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

CÉLULAS PRODUTORAS DE POLIPEPTÍDIO. A presente invenção descreve um ácido nuclélco compreendendo, na direção 5' a 3': a) um primeiro ácido nucléico que codifica um polipeptídio heterólogo sem um códon de parada em fase de leitura, b) um segundo ácido nucléico começando com um sítio doador de splice 5' e terminado por um sítio receptor de splice 3' compreendendo um códon de parada de tradução em fase de leitura e um sinal de poliadenilação, e c) um ácido nucléico que codifica i) pelo menos um fragmento de um domínio transmembrana, ou ii) um peptídio de sinal para uma âncora GPI.
BRPI0712073A 2006-05-17 2007-05-15 ácido nucléico para produção de um polipeptídio ou proteína heteróloga BRPI0712073B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06010146.6 2006-05-17
EP06010146 2006-05-17
PCT/EP2007/004313 WO2007131774A1 (en) 2006-05-17 2007-05-15 Polypeptide producing cells

Publications (3)

Publication Number Publication Date
BRPI0712073A2 true BRPI0712073A2 (pt) 2012-03-06
BRPI0712073B1 BRPI0712073B1 (pt) 2019-11-12
BRPI0712073B8 BRPI0712073B8 (pt) 2021-05-25

Family

ID=37076089

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712073A BRPI0712073B8 (pt) 2006-05-17 2007-05-15 ácido nucléico para produção de um polipeptídio ou proteína heteróloga

Country Status (12)

Country Link
US (2) US8354516B2 (pt)
EP (2) EP2027273B1 (pt)
JP (1) JP4870208B2 (pt)
KR (1) KR101202498B1 (pt)
CN (1) CN101410525B (pt)
AU (1) AU2007251766B2 (pt)
BR (1) BRPI0712073B8 (pt)
CA (1) CA2651478C (pt)
ES (2) ES2543629T3 (pt)
IL (1) IL193721A (pt)
MX (1) MX2008013514A (pt)
WO (1) WO2007131774A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2651478C (en) * 2006-05-17 2015-02-03 Josef Endl Polypeptide producing cells
WO2008070367A2 (en) 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
JP5788796B2 (ja) * 2008-08-28 2015-10-07 ノバルティス アーゲー 終止コドンのリードスルーによるポリペプチドアイソフォームの細胞表面提示
DK2401377T3 (en) 2009-02-27 2016-08-29 Novartis Ag Expression vector system comprising two selection markers
FR2944017B1 (fr) * 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides eclaircissants activateurs du proteasome et compositions les contenant
FR2944016B1 (fr) 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant
FR2944018B1 (fr) * 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant
FR2944797B1 (fr) 2009-04-23 2013-05-10 Isp Investments Inc Hydrolysats peptidiques activateurs du proteasome et compositions les contenant
FR2944798B1 (fr) 2009-04-23 2013-05-10 Isp Investments Inc Hydrolysats peptidiques eclaircissants activateurs du proteasome et compositions les contenant
CN101875916B (zh) * 2009-11-27 2013-04-17 西安交通大学 一种fgfr1高表达的重组hek293细胞及其应用
EP2922962B1 (en) 2012-11-20 2016-12-21 Novartis AG Optimized expression cassette for expressing a polypeptide with high yield
WO2014126254A1 (ja) * 2013-02-18 2014-08-21 協和発酵キリン株式会社 膜結合型タンパク質発現ベクター
US20160017319A1 (en) 2013-03-11 2016-01-21 Audrey Nommay Method of screening cell clones
WO2014171826A1 (en) 2013-04-17 2014-10-23 Stichting Vu-Vumc Treatment of cognitive impairment in depressive disorders
DK3027646T3 (en) 2013-07-31 2018-09-24 Novartis Ag New selection vectors and methods for selecting eukaryotic host cells
DK3083677T3 (da) 2013-12-20 2019-11-25 Novartis Ag Hidtil ukendte eukaryote celler og fremgangsmåder til rekombinant ekspression af et produkt af interesse
KR102288857B1 (ko) 2013-12-20 2021-08-11 노파르티스 아게 신규한 진핵 세포 및 관심 생성물의 재조합 발현 방법
MA39502A (fr) * 2014-02-28 2015-09-03 Glenmark Pharmaceuticals Sa Constructions d'expression et méthodes de sélection des cellules hôtes exprimant des polypeptides
DK3320099T5 (da) 2015-07-09 2024-10-07 Institut National De La Sante Et De La Rech Medicale Inserm Membranforankret eller udskilt antistof til ekspression af lentivirale vektorer
EP3328399B1 (en) 2015-07-31 2023-12-27 Regents of the University of Minnesota Modified cells and methods of therapy
JP6818134B2 (ja) 2016-09-29 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド産生細胞を選択するための改善された方法
GB2604416B (en) 2016-10-18 2023-03-15 Univ Minnesota Tumor infiltating lymphocytes and methods of therapy
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019015677A1 (en) * 2017-07-21 2019-01-24 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED IMMUNOGLOBULIN HEAVY CHAIN ANIMALS
CN107557367B (zh) * 2017-09-08 2020-11-03 北京大学人民医院 Ighg1基因突变体及其应用
AU2021392972A1 (en) * 2020-12-01 2023-06-08 ETH Zürich Dna constructs comprising alternative promoters

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
IL104570A0 (en) * 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP1196566B1 (en) 1999-07-12 2006-02-01 Genentech, Inc. Expression vectors and methods
AUPQ422399A0 (en) 1999-11-24 1999-12-16 University Of New South Wales, The Method of screening transformed or transfected cells
IL136459A0 (en) * 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
US20030033616A1 (en) 2001-07-30 2003-02-13 Star-Lack Joshua Morris Imaging marker transgenes
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
EP1477805A1 (de) 2003-05-12 2004-11-17 ProBioGen AG Verfahren zur Zellselektion
CA2536675A1 (en) 2003-08-29 2005-03-10 Centocor, Inc. A rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method
WO2005040213A1 (en) * 2003-10-16 2005-05-06 Zlb Behring Gmbh MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
EP1733034A4 (en) * 2004-03-15 2010-01-20 Biogen Idec Inc METHOD AND CONSTRUCTS FOR THE EXPRESSION OF POLYPEPTIDE MULTIMERS IN EUKARYONTIC CELLS USING ALTERNATIVE SPLEISSEN
CA2651478C (en) * 2006-05-17 2015-02-03 Josef Endl Polypeptide producing cells

Also Published As

Publication number Publication date
ES2543629T3 (es) 2015-08-20
US20130109058A1 (en) 2013-05-02
AU2007251766B2 (en) 2013-06-20
JP2009537124A (ja) 2009-10-29
ES2573027T3 (es) 2016-06-03
EP2208792A2 (en) 2010-07-21
EP2027273A1 (en) 2009-02-25
EP2208792B1 (en) 2015-05-06
EP2208792A3 (en) 2010-10-27
CN101410525B (zh) 2012-09-05
KR20090003327A (ko) 2009-01-09
EP2027273B1 (en) 2016-04-13
MX2008013514A (es) 2008-10-28
JP4870208B2 (ja) 2012-02-08
US20090311725A1 (en) 2009-12-17
BRPI0712073B1 (pt) 2019-11-12
WO2007131774A1 (en) 2007-11-22
IL193721A (en) 2014-09-30
CN101410525A (zh) 2009-04-15
BRPI0712073B8 (pt) 2021-05-25
IL193721A0 (en) 2011-08-01
CA2651478C (en) 2015-02-03
KR101202498B1 (ko) 2012-11-16
CA2651478A1 (en) 2007-11-22
US8354516B2 (en) 2013-01-15
AU2007251766A1 (en) 2007-11-22
US8541204B2 (en) 2013-09-24

Similar Documents

Publication Publication Date Title
BRPI0712073A2 (pt) cÉlulas produtoras de polipeptÍdio
CL2012000886A1 (es) Polipeptido que comprende dos secuencias aminoacidas que permiten la union especifica al receptor para productos finales de glicosilacion avanzada (rpfga); uno o mas acidos nucleicos que codifican el polipeptido; celula; composicion; metodo para diagnosticar enfermedad o trastorno con rpfga.
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
BRPI0416544A (pt) proteìna de ligação de gag
CO6491059A2 (es) Diferenciacion de las celulas madre mesenquimales
BR112012008862A2 (pt) métodos para produzir uma glicoproteína recombinante e uma eritropoietina humana madura, e, composição
CL2009000284A1 (es) Antagonistas especificos de pro-proteina convertasa subtilisina-kexina tipo 9 humana (pcsk9), composicion farmaceutica que lo comprende; acidos nucleicos que lo codifican; vector, celula y proceso para producir dicho antagonista; util para mejorar un trastorno, afeccion o enfermedad inducida por pcsk9.
CR20120087A (es) Anticuerpos del antígeno carcinoembrionario (cea)
BRPI0911385B8 (pt) polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica
BR112014006509A2 (pt) fibras finas fabricadas a partir de polímero reticulado com composição de aldeído resinoso
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
BR112013004579A2 (pt) proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9
BR112014017165A2 (pt) polipeptídeos de fator quimérico viii e seus usos
PE20140218A1 (es) Composicion farmaceutica
CU20120095A7 (es) Antagonistas de pcsk9
BRPI0607009A2 (pt) stent endoureteral absorvìvel composto reforçada com fibra
ES2570731T3 (es) Método de detección de cáncer
BRPI0914969A2 (pt) método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas
BR112012012160A2 (pt) material e métodos para tratar ou prevenir doenças associadas ao her-3
BRPI0918466B8 (pt) Conjunto de filtro e respectivo método de fabricação
BR112012008665A2 (pt) tratamento de câncer
BR112013002062A2 (pt) peça combustível e processo de produção de uma peça de combustível
BR112013021937A2 (pt) folha, artigo compósito moldado como uma sola de sapato, e processo para produzir um artigo compósito moldado como uma sola de sapato
UA110323C2 (en) Derivative of serum amyloid p and their receipt and application
BR112013000928A2 (pt) sistema de fixação de trilho

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2723 DE 14-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.